个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Li Rong[1] * ; Zhang Hongping[2] ; Li Qingshui[3] ; Yuan Guangwen[4] ; Zhou Yanjie[5] ; Yin Rutie[6] ; Wang He[7] ; Wang Chunyan[8] ; Huang Yi[9] ; Wang Wei[10] ; Yan Xiaojian[11] ; Wu Lingying[4] ; Zhou Qi[1] ;
机构： [1]The Gynecologic Oncology Center, Chongqing University Cancer Hospital, Chongqing, China. [2]Department of Gynecologic, Yunnan Cancer Hospital, Kunming, China. [3]Department of Gynecologic Oncology, Shandong Cancer Hospital, Jinan, China. [4]Department of Gynecologic Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. [5]Department of Gynecologic Oncology, Hunan Cancer Hospital, Changsha, China. [6]Department of Tumor Radiotherapy and Chemotherapy, West China Second University Hospital of Sichuan University, Chengdu, China. [7]Department of Gynecologic, Guangxi Cancer Institute, Nanning, China. [8]Department of Gynecologic Oncology, Liaoning Cancer Hospital, Shenyang, China. [9]Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, China. [10]The Gynecologic Oncology Center, Peking Union Medical College Hospital, Beijing, China. [11]Department of Gynecologic, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
出处：
DOI： 10.1016/j.jncc.2024.04.004

关键词： Ovarian cancer Paclitaxel liposome First-line chemotherapy Efficacy Safety

摘要：
The paclitaxel liposome formulation, encapsulating paclitaxel within a phospholipid bilayer, addresses the insolubility of traditional paclitaxel formulations, thereby reducing toxicity without compromising its antitumor efficacy.This multicenter, open-label, non-inferiority randomized controlled trial (ChiCTR2000038555) evaluates the efficacy and safety of paclitaxel liposome in comparison to the standard regimen of paclitaxel combined with carboplatin (PLC vs. PC) as first-line therapy in patients with epithelial ovarian cancer.An analysis of median progression-free survival (PFS) revealed non-inferior outcomes between 263 patients in the PLC group and 260 patients in the PC group (32.3 vs. 29.9 months, hazard ratio [HR], 0.89 [95% CI, 0.64-1.25]), using a non-inferior margin of 1.3. Although the overall incidence of treatment-related adverse events was comparable between groups, the PLC group experienced significantly fewer non-hematologic toxicities than those treated with the PC regimen.The findings affirm the non-inferiority of paclitaxel liposome compared to the combination of paclitaxel and carboplatin regarding therapeutic efficacy, with an enhanced safety profile marked by reduced non-hematologic toxicities.© 2024 Chinese National Cancer Center. Published by Elsevier B.V.

基金：
This research was funded by the Optimization Study of Treatment Regimen and Clinical Practice in Ovarian Cancer (grant number: 2016YFC1303702)
语种：
外文
PubmedID：
第一作者：
第一作者机构： [1]The Gynecologic Oncology Center, Chongqing University Cancer Hospital, Chongqing, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Li Rong,Zhang Hongping,Li Qingshui,et al.Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial[J].Journal Of The National Cancer Center.2024,4(2):135-141.doi:10.1016/j.jncc.2024.04.004.
APA：
Li Rong,Zhang Hongping,Li Qingshui,Yuan Guangwen,Zhou Yanjie...&Zhou Qi.(2024).Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial.Journal Of The National Cancer Center,4,(2)
MLA：
Li Rong,et al."Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial".Journal Of The National Cancer Center 4..2(2024):135-141

相关文献

[1]Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer [2]Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatinradiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial [3]Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. [4]The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy [5]贝伐单抗联合化疗一线治疗转移性实体瘤有效性和安全性的Meta分析 [6]Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial [7]Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer [8]Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study [9]First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [10]Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis

资源点击量：53080 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号